CombiRx trial recruiting people with MS

June 2006
Inside MS;Jun/Jul2006, Vol. 24 Issue 3, p33
Academic Journal
The article reports on the launching of a trial called CombiRx aimed to verify a pilot trial of combination chemotherapy for multiple sclerosis (MS) as of June 2006. An earlier study of Avonex taken with Copaxone suggested that the combination was safe for people with relapsing forms of MS. Individuals with relapsing-remitting MS are needed as study volunteers. The study will be conducted at a number of U.S. and Canadian centers.


Related Articles

  • Multiple medication use associated with ED.  // Urology Times;Dec2011, Vol. 39 Issue 13, p8 

    The article focuses on the study by Kaiser Permanente Los Angeles Medical Center researchers regarding the association of multiple medication use with erectile dysfunction's (ED) severity.

  • Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma. Axelrod, M; Ou, Z; Brett, L K; Zhang, L; Lopez, E R; Tamayo, A T; Gordon, V; Ford, R J; Williams, M E; Pham, L V; Weber, M J; Wang, M L // Leukemia (08876924);Feb2014, Vol. 28 Issue 2, p407 

    A letter to the editor is presented regarding the combinatorial drug screening of targeted drugs combined with ibrutinib for mantle cell lymphoma (MCL).

  • Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.  // Current Medical Literature: Multiple Sclerosis;2010, Vol. 2 Issue 3, p80 

    In this article the author discusses a study on the effectiveness of natalizumab with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis (RRMS). It is based on the 2-year magnetic resonance imaging (MRI) data from the Safety and Efficacy of Natalizumab in Combination...

  • Safety and Efficacy of Dihydroartemisinin-Piperaquine in Falciparum Malaria: A Prospective Multi-Centre Individual Patient Data Analysis. Zwang, Julien; Ashley, Elizabeth A.; Karema, Corine; D'Alessandro, Umberto; Smithuis, Frank; Dorsey, Grant; Janssens, Bart; Mayxay, Mayfong; Newton, Paul; Singhasivanon, Pratap; Stepniewska, Kasia; White, Nicholas J.; Nosten, Fran├žois // PLoS Clinical Trials;Jul2009, Vol. 6 Issue 7, Special section p1 

    Background: The fixed dose antimalarial combination of dihydroartemisinin-piperaquine (DP) is a promising new artemisinin-based combination therapy (ACT). We present an individual patient data analysis of efficacy and tolerability in acute uncomplicated falciparum malaria, from seven published...

  • Comparison of the efficacy of gentamicin for 5 days plus doxycycline for 8 weeks versus streptomycin for 2 weeks plus doxycycline for 45 days in the treatment of human brucellosis: a randomized clinical trial. Roushan, M. R. Hasanjani; Amiri, M. J. Soleimani; Janmohammadi, N.; Hadad, M. Sadeghi; Javanian, M.; Baiani, M.; Bijani, A. // Journal of Antimicrobial Chemotherapy (JAC);May2010, Vol. 65 Issue 5, p1028 

    Objectives: To compare the efficacy of gentamicin for 5 days plus doxycycline for 8 weeks with streptomycin for 2 weeks plus doxycycline for 45 days in the treatment of human brucellosis. Methods: In each arm of the study, 82 patients older than 10 years randomly received 5 mg/kg gentamicin once...

  • ImClone: Erbitux positioned to become gold standard in advanced head and neck cancer.  // PharmaWatch: Monthly Review;May2007, Vol. 6 Issue 5, p7 

    The article reports that the use of the drug Erbitux, in combination with platinum-based chemotherapy, enhances survival in the treatment of recurrent or metastatic head and neck cancer. This was revealed by a phase III clinical trial of the drug which is manufactured by ImClone Systems Inc. The...

  • Safe and well tolerated. Fleischmann, Roy; Goodson, Nicola; Elewaut, Dirk // Rheumatology;Nov2011, Vol. 50 Issue 11, p1942 

    The authors reflect on how to determine what medication is safe and well tolerated by a patient with rheumatoid arthritis (RA). They examine the cases in which the patients have comorbidities that complicate the selection of medication or create problem on the use of an effective treatment. They...

  • Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer. Zang, D. Y.; Lee, B. H.; H.-Park, C.; Song, H. H.; Kim, H. J.; Jung, J. Y.; Kim, J. H.; Kim, H. Y.; Kwon, J. H.; Hwang, S. W.; Park, S. R.; Park, C. H.; Kim, K. O.; M.-Kim, J.; Jang, K. M. // Annals of Oncology;May2009, Vol. 20 Issue 5, p892 

    Background: To evaluate the efficacy and safety of the combination of oxaliplatin and S-1 (OS) in treating metastatic colorectal cancer. Patients and methods: Eligible patients were those with measurable lesions, no previous history of chemotherapy (except adjuvant chemotherapy), an age of...

  • Combination therapies useful for severe scabies cases. Petrou, Illya // Dermatology Times;Jun2014, Vol. 35 Issue 6, p25 

    The article discusses how topical permethrin cream 5% in combination with oral ivermectin remains the treatment of choice for scabies. Topics discussed include Lindane which is still considered as a back-up treatment although it has fallen into disuse in the U.S. due to the possibility of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics